NCT03172624 · OUTCOME

Best Overall Response Rate

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer · Source last updated 2025-12-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 2 years

What was measured

using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Groups in this outcome

R/M Adenoid Cystic Carcinoma (ACC)

Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

R/M SGC of Any Histology, Except ACC (Non ACC)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
R/M Adenoid Cystic Carcinoma (ACC)	32
R/M SGC of Any Histology, Except ACC (Non ACC)	32

Reported measurements

Source class 1

Partial Response

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R/M Adenoid Cystic Carcinoma (ACC)	2	Not reported	Not reported	Not reported	Not reported
R/M SGC of Any Histology, Except ACC (Non ACC)	5	Not reported	Not reported	Not reported	Not reported

Stable Disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R/M Adenoid Cystic Carcinoma (ACC)	17	Not reported	Not reported	Not reported	Not reported
R/M SGC of Any Histology, Except ACC (Non ACC)	8	Not reported	Not reported	Not reported	Not reported

Progressive Disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R/M Adenoid Cystic Carcinoma (ACC)	13	Not reported	Not reported	Not reported	Not reported
R/M SGC of Any Histology, Except ACC (Non ACC)	18	Not reported	Not reported	Not reported	Not reported

Not Evaluable

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R/M Adenoid Cystic Carcinoma (ACC)	0	Not reported	Not reported	Not reported	Not reported
R/M SGC of Any Histology, Except ACC (Non ACC)	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2
group Id
OG001
value
5
title
Partial Response
measurements
group Id
OG000
value
17
group Id
OG001
value
8
title
Stable Disease
measurements
group Id
OG000
value
13
group Id
OG001
value
18
title
Progressive Disease
measurements
group Id
OG000
value
0
group Id
OG001
value
1
title
Not Evaluable

denoms

counts
group Id
OG000
value
32
group Id
OG001
value
32
units
Participants

description

using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

groups

description
Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
id
OG000
title
R/M Adenoid Cystic Carcinoma (ACC)
description
Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
id
OG001
title
R/M SGC of Any Histology, Except ACC (Non ACC)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

2 years

title

Best Overall Response Rate

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice